Safety & Performance Study of Lumen Biomedical's FiberNet Distal Protection System for the Treatment of Renal Artery Stenosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the procedural safety and filter efficiency of the FiberNet® Embolic Protection System when used in conjunction with the Boston Scientific Express SD Stent System for primary stenting of ostial atherosclerotic renal lesions in patients with atherosclerotic renal artery stenosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

EPIC US Feasibility Study: Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting

NCT00346515

Carotid Artery Stenosis

COMPLETED NA

A Prospective, Multi-center, Single Arm Study Evaluating the Express™ Renal Premounted Stent System in the Treatment of Atherosclerotic Lesions in the Aortorenal Ostium.

NCT00597142

Atherosclerotic Lesions in the Aortorenal Ostium

COMPLETED PHASE4

EPIC European Study: Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting

NCT00309803

Carotid Artery Stenosis

COMPLETED NA

EPIC US Pivotal Study

NCT00460187

Percutaneous Intervention of the Carotid Arteries.

COMPLETED NA

Safety and Effectiveness of the Peripheral Balloon-Expandable Covered Stent System for Iliac Artery Stenosis/Occlusion. (SELECT)

NCT06605209

Peripheral Artery Disease (PAD)

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Stenting in the Treatment of Pts w/a High Grade Ostial Atherosclerotic Renal Lesion(s).

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment, Open label, Single Group Assignment

Group Type OTHER

Lumen Biomedical FiberNet Embolic Protection System

Intervention Type DEVICE

to demonstrate the safety and filter efficiency of the Lumen Biomedical FiberNet Embolic Protection System during the performance of primary renal stenting in the treatment of pts with a high grade ostial atherosclerotic renal lesion(s).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lumen Biomedical FiberNet Embolic Protection System

to demonstrate the safety and filter efficiency of the Lumen Biomedical FiberNet Embolic Protection System during the performance of primary renal stenting in the treatment of pts with a high grade ostial atherosclerotic renal lesion(s).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 and ≤ 85 years.
2. Subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed an IRB approved consent form.
3. Subject understands the duration of the study and it's follow up visit requirements.
4. Unilateral or bilateral atherosclerotic de novo renal artery stenosis (RAS) associated with any or all of the following:

1. SBP \>140 despite ≥3 anti-hypertensive medications
2. Estimated Glomerular Filtration Rate (eGFR) ≥30-≤70 cc/min calculated using the Modified Diet in Renal Disease (MDRD) formula
3. Recurrent episodes of decompensated heart failure
4. Recurrent episodes of "flash" pulmonary edema

1. ≥70% \<100% renal artery stenosis (by visual estimate) involving unilateral, bilateral renal arteries or solitary renal artery.
2. Renal pole-to-pole length \>7cm.
3. Lesion ≤15 mm from the aorto-ostial junction.
4. Renal artery reference lumen diameter ≥3.5 - ≤7 mm for FiberNet placement.

Exclusion Criteria

1. Estimated life expectancy \<12 months.
2. Estimated Glomerular Filtration Rate (eGFR) \<30 cc/min.
3. Renal pole-to-pole length \<7cm on side of diseased kidney.
4. No history of transplanted kidneys or polycystic kidney disease.
5. Uncontrolled hypercoagulability.
6. Known allergies or sensitivities to heparin, aspirin, other anti-coagulant/antiplatelet therapies, nitinol and stainless steel.
7. Known allergy to contrast media that cannot adequately be pre-medicated prior to study procedure.
8. Patient refuses possible temporary or permanent hemodialysis.
9. Refuses possible surgery for repair of access site or renal artery.
10. Known severe coronary or carotid disease likely to require surgical treatment after enrollment or during follow-up period.
11. Uncompensated congestive heart failure.
12. Current enrollment in any investigational study wherein patient participation has not been completed.
13. Cardiovascular surgical or cardiovascular interventional procedures (including, but not limited to, aortic, renal, cardiac, carotid, femoro-popliteal, and below the knee) within 30 days prior to enrollment in this study.
14. Planned or predicted cardiovascular surgical or interventional procedures outside of the affected renal artery (including, but not limited to, aortic, renal, cardiac, carotid, contralateral femoro-popliteal, and contralateral below the knee) within 30 days after entry into this study and prior to completion of the 30 day follow-up.
15. Pregnancy, breast-feeding or plans to become pregnant in female of child bearing potential.
16. Any patient who in the opinion of the investigator would not be a good candidate for enrollment.

1. Early bifurcation of the main renal artery preventing complete embolic protection of the kidney with the FiberNet.
2. Fibromuscular Dysplasia.
3. Presence of thrombus at the lesion site.
4. Non-ostial atherosclerosis (lesion \>15mm from the renal ostium).
5. Subintimal guidewire placement resulting in dissection of the renal artery or aorta, or perforation of the renal artery or aorta prior to deployment of the device.
6. Severe calcification likely to prevent the passage of the device. -

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No